Concurrently, advances have been made in modifying conventional myeloablative transplant regimens to allow for the treatment of older patients. However, regimen-related toxicities have remained ...

Myeloablative or high-dose chemotherapy with autologous hematopoietic progenitor cell rescue (HDC/AuHCR) was first evaluated in the treatment of brain tumors in the late 1970s. Historically ...

Although HCT can cure AML, high-intensity preparative regimens (ie, myeloablative conditioning [MAC]) lead to considerable toxicity and treatment-related mortality (TRM). This prompted development of ...

However, use of CY+TBI was associated with a significant risk of secondary myelodysplasia and secondary acute myeloblastic leukemia, resulting in 15 patient deaths. These mature data confirm that ...

We compared myeloablative CD34+ selected autologous hematopoietic stem-cell transplantation with immunosuppression by means of 12 monthly infusions of cyclophosphamide in patients with scleroderma.

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window ORLANDO -- Myeloablative conditioning (MAC) led to a long-term survival benefit versus reduced-intensity conditioning ...

Patients in the high-dose chemotherapy group received carmustine (or busulfan if not available) and thiotepa followed by ASCT, while those in the non-myeloablative consolidation arm received two ...

Patients received myeloablative conditioning followed by mobilized peripheral-blood stem-cell transplants. Sitagliptin was given orally at a dose of 600 mg every 12 hours starting the day before ...

Pulmonary function remained stable -- and in some ways improved -- among patients with sickle cell disease (SCD) who underwent non-myeloablative hematopoietic cell transplant (HCT), a prospective ...

Non-myeloablative allogeneic HSCT shows promise for adults with sickle cell disease Add topic to email alerts Receive an email when new articles are posted on ...